Donor Lung Pretreatment with Surfactant in Experimental Transplantation Preserves Graft Hemodynamics and Alveolar Morphology

Abstract

In experimental lung transplantation, the reduction of endogenous surfactant properties occurs after graft preservation and transplant reperfusion. The aim of this study was to evaluate the efficacy of donor lung pretreatment with exogenous surfactant on graft damage after ischemia and reperfusion. Fourteen (control group A, n = 8; study group B,n= 6) young female white pigs (mean weight 27 ± 3.5 kg) were used in a newly developed autotransplantation model within situcold ischemia. In study group B, before thoracotomy, 1.5 ml/kg surfactant apoprotein-A-free surfactant was administrated into the left main bronchus via flexible bronchoscopy. Belzer UW solution was used for lung preservation. Cold ischemia was achieved for 3 hr with interlobar lung parenchyma temperature at 8 ± 1.3°C, and central temperature maintained at 37.20 ± 0.5°C. Animals were sacrificed after 3 hr of graft reperfusion. At the end of reperfusion, pulmonary vascular resistance index (was 447.80 dyn/sec.cm⁵.m²(±66.8) in group A vs 249.51 in group B (P< 0.001) and serum nitric oxide was adequately preserved. The mean alveolar surface area estimated by computerized morphometry was 5280.84 (4991.1) μm²(group A) vs 3997.89 (3284.70) μm²(group B;P< 0.005). Histology revealed milder macrophage and lymphocyte infiltration in group B at the end of reperfusion. Pretreatment of donor lung with an surfactant apoprotein-A -free surfactant agent appears to be beneficial in terms of maintaining serum NO and reducing hemodynamic disturbances. Furthermore, alveolar histology and stereomorphology are better preserved.

Get full access to this article

View all access options for this article.

References

Lewis JFR, Novick J, Veldhuizen RAW. Surfactant in Lung Injury and Lung Transplantation. New York: Chapman & Hall, 1997.

Novick RJ, Gehman KE, Ali IS, Lee J. Lung preservation: The importance of endothelial and alveolar type II cell integrity. Ann Thorac Surg 62 : 302–314, 1996.

Klepetko W, Lohninger A, Wissen W, Mueller MR, Khunl-Brady G, Windisch A, Eckerberger F, Wolner E. Pulmonary surfactant in bronchoalveolar lavage after canine lung transplantation: Effect of L-carnitine application. J Thorac. Cardiovasc Surg 99 : 1048–1058, 1990.

Andrade R, Solien E, Wangensteen OD, Tsai MY, Kshettry VR, Bolman RM 3rd. Surfactant dysfunction in lung preservation. Transplantation 60 : 536–541, 1995.

Cockshutt A, Weitz J, Possmayer F. Pulmonary surfactant-associated protein A enhances the surface activity of lipid extract surfactant and reverse inhibition by blood proteins in vitro. Biochemistry 29 : 8424–8429, 1990.

Kuroki Y, Mason RJ, Voelker DR. Pulmonary surfactant apoprotein A structure and modulation of surfactant secretion by rat alveolar type II cells. J Biol Chem 263 : 3388–3394, 1988.

Hohlfeld JM, Tiryaki E, Hamm H, Hoymann HG, Krug N, Haverich A, Fabel H. Pulmonary surfactant activity is impaired in lung transplant recipients. Am J Respir Crit Care Med 158 : 706–712, 1998.

Erasmus ME, Petersen AH, Oetomo SB, Prop J. The function of surfactant is impaired during the reimplantation response in rat lung transplants. J Heart Lung Transplant 13 : 791–802, 1994.

Veldhuizen RA, Lee J, Sandler D, et al. Alterations in pulmonary surfactant composition and activity after experimental lung transplantation. Am Rev Respir Dis 148 : 208–215, 1993.

10.

Dougenis D, Tzorakoelefterakis E, Filos KS, et al. Experimental single lung transplantation in pigs. Intern J Artif Organ 15 : 533, 1992.

11.

Filos K, Dougenis D, Tzorakoelefterakis E, et al. The prognostic value of continuous SvO₂ monitoring by fiberoptic oxymetry in single lung transplantation. A pilot study. Intens Care Med 18(suppl): 117, 1992.

12.

Swindell MM. Anesthetic and perioperative techniques in swine. Wilmington, MA: Charles River Laboratories, CRL Tech Bull (winter), 1991.

13.

Hawk CT, Leary SL. Formulatory for Laboratory Animals. Iowa: American College of Laboratory Animal Medicine, Iowa State Pr (Sd) p78, 1995.

14.

Kouloukoussa M, Panagopoulou E, Marinos E. The in vitro effect of the tumor promoter 12-O-tetradecanoyphorbol-13-acete on Sertoli cell morphology. Cancer Detect Prev 23 : 280–289, 1999.

15.

Pipili-Synetos E, Kritikou S, Papadimitriou E, et al. Nitric oxide synthase expression, enzyme activity and NO production during angiogenesis in the chicken chorioallantoic membrane. Br J Pharmacol 129 : 207–213:39–78 2000.

16.

Carvounis CP. Handbook of biostatistics. A review and text. New York: Parthenon Publishing, 2000.

17.

Spragg R, Lewis J. Pathology of the surfactant system of the mature lung. Am J Respir Crit Care Med 163 : 280–282, 2001.

18.

Report of the ATS workshop on lung transplantation: Lung transplantation. Am Rev Resp Dis 147 : 772–776, 1993.

19.

Novick RJ, Menkis AH, McKenzie FN. New trends in lung preservation: A collective review. J Heart Lung Transplant 11 : 377–392, 1992.

20.

Cooper JV, Vreim CE. Biology of lung preservation for transplantation. Am Rev Resp Dis 146 : 803–807, 1992.

21.

Burkhardt R, Van Golde LMG. Lipids and lipid metabolism in the lung. Lung Biol Tzorakoelefterakis E. Health Dis 41 : 591–599, 1989.

22.

Hallman M, Maasilta P, Sipila I, Tahvanainen J. Composition and faction of pulmonary surfactant in adult respiratory distress syndrome. Eur Resp. J 2(Suppl 3): 104s–108s, 1989.

23.

Hallman M, Spragg R, Harrell JH, Moser KM, Gluck S. Evidence of lung surfactant abnormality in respiratory failure. J Clin Invest 70 : 673–683, 1982.

24.

Li CG, Rand MJ. Evidence that part of the NANC relaxant response of the guinea pig trachea to electrical field stimulation is mediated by nitric oxide. Br J Pharmacol 102 : 91–94, 1991.

25.

Dinh–Xuan AT. Endothelial modulation of pulmonary vascular tone. Eur Respir J 51 : 757–762, 1992.

26.

Barnes PJ. Nitric oxide and airways. Eur Respir J 6 : 163–165, 1993.

27.

Tsao PS, Lefer AM. Time course and mechanism of endothelial dysfunction is isolated ischemic and hypoxic perfused rat hearts. Am J Physiol 259 : H1660–H1666, 1990.

28.

Thuchiya M, Tokai H, Takehara Y, et al. Interrelation between oxygen tension and nitric oxide in the respiratory system. Am J Respir Crit Care Med 162 : 1257–1261, 2000.

29.

Dugas B, Debre P, Moncada S. Nitric oxide, a vital poison inside the immune and inflammatory network. Res Immunol 146 : 664–670, 1995.

30.

Hancock JT. Superoxide, hydrogen peroxide and nitric oxide as signaling molecules: Their production and role in disease. Br J Biomed. Sci 54 : 38–46, 1997.

31.

Kubes P, Szuki M, Granger DN. Nitric oxide: An endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 88 : 4651–4655, 1991.

32.

Lefer AM, Lefer DJ. Pharmacology of the endothelium in ischemia-reperfusion and circulatory shock. Annu Rev Pharmacol Toxicol 33 : 71–90, 1993.

33.

Moilanen E, Vapaatalo H. Nitric oxide in inflammation and immune response. Ann Med 27 : 359–367, 1995.

34.

Schroeder RA, Kuo PC. Nitric oxide: Physiology and pharmacology. Anesth Analg 81 : 1052–1059, 1995.

35.

Merritt TA, Hallman M. Surfactant replacement. A new era with many challenges for neonatal medicine. Am J Dis Child 142 : 1333–1339, 1988.

36.

Sano H, Sohma H, Muta T, Nomura S, Voeker DR, Kuroki Y. Pulmonary surfactant protein A modulates the cellular response to smooth and rough lipopolysaccharides by interaction with CD 14. J Immunol 163 : 387–395, 1999.

37.

Kramer B, Jobe A. Surfactant protein A recruits neutrophils into the lungs of ventilated preterm lambs. Am J Respir Crit Care Med 163 : 158–165, 2001.

38.

Awasthi S, Coalson JJ, Yoder BA, Crouch E, King RJ. Deficiencies in lung surfactant proteins A and D are associated with lung infection in very premature neonatal baboons. Am J Respir Crit Care Med 163 : 389–397, 2001.

39.

Walmrath D, Günther A, Chofrani HA, Schermuly R, Scheider T, Grimminger F, Seeger W. Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis. Am J Respir Crit Care Med 154 : 57–62, 1996.